Does the media prefer SABS or ALVO?

In the previous week, SAB Biotherapeutics had 17 more articles in the media than Alvotech. MarketBeat recorded 21 mentions for SAB Biotherapeutics and 4 mentions for Alvotech. Alvotech's average media sentiment score of 0.97 beat SAB Biotherapeutics' score of 0.33 indicating that Alvotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SAB Biotherapeutics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Alvotech 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SABS or WVE?

In the previous week, SAB Biotherapeutics had 4 more articles in the media than WAVE Life Sciences. MarketBeat recorded 21 mentions for SAB Biotherapeutics and 17 mentions for WAVE Life Sciences. WAVE Life Sciences' average media sentiment score of 0.49 beat SAB Biotherapeutics' score of 0.33 indicating that WAVE Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SAB Biotherapeutics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral WAVE Life Sciences 7 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Is CRVS or SABS more profitable?

SAB Biotherapeutics' return on equity of -6.74% beat Corvus Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Corvus Pharmaceuticals N/A -36.15% -33.62% SAB Biotherapeutics N/A -6.74% -6.06%

Does the media prefer CRVS or SABS?

In the previous week, Corvus Pharmaceuticals had 4 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 25 mentions for Corvus Pharmaceuticals and 21 mentions for SAB Biotherapeutics. SAB Biotherapeutics' average media sentiment score of 0.33 beat Corvus Pharmaceuticals' score of -0.12 indicating that SAB Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corvus Pharmaceuticals 5 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral SAB Biotherapeutics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor MGTX or SABS?

In the previous week, SAB Biotherapeutics had 8 more articles in the media than MeiraGTx. MarketBeat recorded 21 mentions for SAB Biotherapeutics and 13 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 1.05 beat SAB Biotherapeutics' score of 0.33 indicating that MeiraGTx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MeiraGTx 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SAB Biotherapeutics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is SABS or ORIC more profitable?

SAB Biotherapeutics' return on equity of -6.74% beat Oric Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets SAB Biotherapeutics N/A -6.74% -6.06% Oric Pharmaceuticals N/A -35.35% -33.39%

Does the media prefer SABS or ORIC?

In the previous week, SAB Biotherapeutics had 4 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 21 mentions for SAB Biotherapeutics and 17 mentions for Oric Pharmaceuticals. Oric Pharmaceuticals' average media sentiment score of 0.59 beat SAB Biotherapeutics' score of 0.33 indicating that Oric Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SAB Biotherapeutics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Oric Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

SAB Biotherapeutics (SABS) Competitors

$3.70 -0.05 (-1.33%)

Closing price 04:00 PM Eastern

Extended Trading

$3.64 -0.06 (-1.49%)

As of 07:34 PM Eastern

Compare

SABS vs. ALVO, WVE, CRVS, MGTX, and ORIC

Should you buy SAB Biotherapeutics stock or one of its competitors? SAB Biotherapeutics's main competitors and comparable companies include Alvotech (ALVO), WAVE Life Sciences (WVE), Corvus Pharmaceuticals (CRVS), MeiraGTx (MGTX), and Oric Pharmaceuticals (ORIC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does SAB Biotherapeutics compare to Alvotech?

SAB Biotherapeutics (NASDAQ:SABS) and Alvotech (NASDAQ:ALVO) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings and risk.

In the previous week, SAB Biotherapeutics had 17 more articles in the media than Alvotech. MarketBeat recorded 21 mentions for SAB Biotherapeutics and 4 mentions for Alvotech. Alvotech's average media sentiment score of 0.97 beat SAB Biotherapeutics' score of 0.33 indicating that Alvotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SAB Biotherapeutics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alvotech	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SAB Biotherapeutics currently has a consensus price target of $12.00, indicating a potential upside of 224.32%. Alvotech has a consensus price target of $7.60, indicating a potential upside of 87.65%. Given SAB Biotherapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe SAB Biotherapeutics is more favorable than Alvotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Alvotech	2 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.14

7.8% of SAB Biotherapeutics shares are held by institutional investors. 7.4% of SAB Biotherapeutics shares are held by insiders. Comparatively, 0.5% of Alvotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Alvotech has higher revenue and earnings than SAB Biotherapeutics. Alvotech is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	$1.32M	255.05	$13.27M	-$1.30	N/A
Alvotech	$588.90M	2.08	$27.92M	-$0.25	N/A

SAB Biotherapeutics has a net margin of 0.00% compared to Alvotech's net margin of -14.36%. SAB Biotherapeutics' return on equity of -6.74% beat Alvotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	N/A	-6.74%	-6.06%
Alvotech	-14.36%	-11.92%	-7.59%

SAB Biotherapeutics has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market. Comparatively, Alvotech has a beta of 0.18, meaning that its share price is 82% less volatile than the broader market.

Summary

SAB Biotherapeutics beats Alvotech on 12 of the 16 factors compared between the two stocks.

How does SAB Biotherapeutics compare to WAVE Life Sciences?

SAB Biotherapeutics (NASDAQ:SABS) and WAVE Life Sciences (NASDAQ:WVE) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

In the previous week, SAB Biotherapeutics had 4 more articles in the media than WAVE Life Sciences. MarketBeat recorded 21 mentions for SAB Biotherapeutics and 17 mentions for WAVE Life Sciences. WAVE Life Sciences' average media sentiment score of 0.49 beat SAB Biotherapeutics' score of 0.33 indicating that WAVE Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SAB Biotherapeutics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
WAVE Life Sciences	7 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

SAB Biotherapeutics has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.26, indicating that its share price is 226% less volatile than the broader market.

SAB Biotherapeutics has higher earnings, but lower revenue than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	$1.32M	255.05	$13.27M	-$1.30	N/A
WAVE Life Sciences	$42.73M	24.95	-$204.38M	-$1.09	N/A

7.8% of SAB Biotherapeutics shares are owned by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are owned by institutional investors. 7.4% of SAB Biotherapeutics shares are owned by company insiders. Comparatively, 24.3% of WAVE Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

SAB Biotherapeutics currently has a consensus target price of $12.00, indicating a potential upside of 224.32%. WAVE Life Sciences has a consensus target price of $22.53, indicating a potential upside of 316.44%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe WAVE Life Sciences is more favorable than SAB Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94

SAB Biotherapeutics has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -309.73%. SAB Biotherapeutics' return on equity of -6.74% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	N/A	-6.74%	-6.06%
WAVE Life Sciences	-309.73%	-50.36%	-40.06%

Summary

WAVE Life Sciences beats SAB Biotherapeutics on 9 of the 17 factors compared between the two stocks.

How does SAB Biotherapeutics compare to Corvus Pharmaceuticals?

Corvus Pharmaceuticals (NASDAQ:CRVS) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, risk, earnings, valuation and institutional ownership.

Corvus Pharmaceuticals has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market. Comparatively, SAB Biotherapeutics has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market.

46.6% of Corvus Pharmaceuticals shares are held by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are held by institutional investors. 19.7% of Corvus Pharmaceuticals shares are held by insiders. Comparatively, 7.4% of SAB Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Corvus Pharmaceuticals presently has a consensus target price of $33.33, suggesting a potential upside of 123.86%. SAB Biotherapeutics has a consensus target price of $12.00, suggesting a potential upside of 224.32%. Given SAB Biotherapeutics' higher possible upside, analysts plainly believe SAB Biotherapeutics is more favorable than Corvus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

SAB Biotherapeutics' return on equity of -6.74% beat Corvus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-36.15%	-33.62%
SAB Biotherapeutics	N/A	-6.74%	-6.06%

In the previous week, Corvus Pharmaceuticals had 4 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 25 mentions for Corvus Pharmaceuticals and 21 mentions for SAB Biotherapeutics. SAB Biotherapeutics' average media sentiment score of 0.33 beat Corvus Pharmaceuticals' score of -0.12 indicating that SAB Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corvus Pharmaceuticals	5 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
SAB Biotherapeutics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

SAB Biotherapeutics has higher revenue and earnings than Corvus Pharmaceuticals. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.61	N/A
SAB Biotherapeutics	$1.32M	255.05	$13.27M	-$1.30	N/A

Summary

SAB Biotherapeutics beats Corvus Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does SAB Biotherapeutics compare to MeiraGTx?

MeiraGTx (NASDAQ:MGTX) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

MeiraGTx currently has a consensus target price of $26.17, suggesting a potential upside of 93.54%. SAB Biotherapeutics has a consensus target price of $12.00, suggesting a potential upside of 224.32%. Given SAB Biotherapeutics' higher probable upside, analysts plainly believe SAB Biotherapeutics is more favorable than MeiraGTx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, SAB Biotherapeutics had 8 more articles in the media than MeiraGTx. MarketBeat recorded 21 mentions for SAB Biotherapeutics and 13 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 1.05 beat SAB Biotherapeutics' score of 0.33 indicating that MeiraGTx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MeiraGTx	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SAB Biotherapeutics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

MeiraGTx has a net margin of 19.87% compared to SAB Biotherapeutics' net margin of 0.00%. SAB Biotherapeutics' return on equity of -6.74% beat MeiraGTx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MeiraGTx	19.87%	-226.79%	34.92%
SAB Biotherapeutics	N/A	-6.74%	-6.06%

SAB Biotherapeutics has lower revenue, but higher earnings than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$81.39M	15.38	-$114.20M	-$1.48	N/A
SAB Biotherapeutics	$1.32M	255.05	$13.27M	-$1.30	N/A

67.5% of MeiraGTx shares are owned by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are owned by institutional investors. 7.4% of MeiraGTx shares are owned by company insiders. Comparatively, 7.4% of SAB Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

MeiraGTx has a beta of 1.23, suggesting that its stock price is 23% more volatile than the broader market. Comparatively, SAB Biotherapeutics has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market.

Summary

MeiraGTx beats SAB Biotherapeutics on 10 of the 17 factors compared between the two stocks.

How does SAB Biotherapeutics compare to Oric Pharmaceuticals?

SAB Biotherapeutics (NASDAQ:SABS) and Oric Pharmaceuticals (NASDAQ:ORIC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

SAB Biotherapeutics has higher revenue and earnings than Oric Pharmaceuticals. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	$1.32M	255.05	$13.27M	-$1.30	N/A
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A

In the previous week, SAB Biotherapeutics had 4 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 21 mentions for SAB Biotherapeutics and 17 mentions for Oric Pharmaceuticals. Oric Pharmaceuticals' average media sentiment score of 0.59 beat SAB Biotherapeutics' score of 0.33 indicating that Oric Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SAB Biotherapeutics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oric Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SAB Biotherapeutics' return on equity of -6.74% beat Oric Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	N/A	-6.74%	-6.06%
Oric Pharmaceuticals	N/A	-35.35%	-33.39%

SAB Biotherapeutics currently has a consensus target price of $12.00, indicating a potential upside of 224.32%. Oric Pharmaceuticals has a consensus target price of $19.45, indicating a potential upside of 40.26%. Given SAB Biotherapeutics' higher probable upside, equities research analysts plainly believe SAB Biotherapeutics is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Oric Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

7.8% of SAB Biotherapeutics shares are owned by institutional investors. Comparatively, 95.1% of Oric Pharmaceuticals shares are owned by institutional investors. 7.4% of SAB Biotherapeutics shares are owned by company insiders. Comparatively, 5.7% of Oric Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

SAB Biotherapeutics has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market. Comparatively, Oric Pharmaceuticals has a beta of 1.02, suggesting that its share price is 2% more volatile than the broader market.

Summary

SAB Biotherapeutics beats Oric Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Get SAB Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SABS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SABS vs. The Competition

Export

Metric	SAB Biotherapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$341.20M	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	-2.85	10.67	269.06	25.28
Price / Sales	255.05	1,294.08	602.43	91.76
Price / Cash	10.98	102.88	70.48	50.90
Price / Book	1.57	16.78	12.91	6.24
Net Income	$13.27M	-$13.32M	$3.45B	$347.60M
7 Day Performance	-5.13%	1.74%	1.12%	1.07%
1 Month Performance	2.78%	1.60%	1.79%	1.03%
1 Year Performance	67.42%	56.43%	67.69%	20.77%

SAB Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SABS SAB Biotherapeutics	2.6876 of 5 stars	$3.70 -1.3%	$12.00 +224.3%	+74.4%	$341.20M	$1.32M	N/A	140	Positive News
ALVO Alvotech	3.1578 of 5 stars	$3.84 +1.3%	$7.60 +97.9%	-54.4%	$1.14B	$588.90M	N/A	1,460	Positive News Upcoming Earnings Analyst Forecast
WVE WAVE Life Sciences	3.2983 of 5 stars	$6.00 +4.5%	$22.53 +275.5%	-40.6%	$1.13B	$42.73M	N/A	240
CRVS Corvus Pharmaceuticals	2.3873 of 5 stars	$13.92 +4.1%	$33.33 +139.5%	+202.8%	$1.12B	N/A	N/A	30	News Coverage Analyst Revision
MGTX MeiraGTx	3.7683 of 5 stars	$12.29 +3.5%	$26.00 +111.6%	+51.9%	$1.10B	$81.39M	N/A	300	Trending News Earnings Report Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SABS) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SAB Biotherapeutics (SABS) Competitors

SABS vs. ALVO, WVE, CRVS, MGTX, and ORIC

How does SAB Biotherapeutics compare to Alvotech?

Summary

How does SAB Biotherapeutics compare to WAVE Life Sciences?

Summary

How does SAB Biotherapeutics compare to Corvus Pharmaceuticals?

Summary

How does SAB Biotherapeutics compare to MeiraGTx?

Summary

How does SAB Biotherapeutics compare to Oric Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SABS vs. The Competition

SAB Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SAB Biotherapeutics (SABS) Competitors

SABS vs. ALVO, WVE, CRVS, MGTX, and ORIC

How does SAB Biotherapeutics compare to Alvotech?

Does the media prefer SABS or ALVO?

Do analysts recommend SABS or ALVO?

Do institutionals and insiders believe in SABS or ALVO?

Which has stronger valuation & earnings, SABS or ALVO?

Is SABS or ALVO more profitable?

Which has more volatility and risk, SABS or ALVO?

Summary

How does SAB Biotherapeutics compare to WAVE Life Sciences?

Does the media prefer SABS or WVE?

Which has more volatility & risk, SABS or WVE?

Which has preferable earnings and valuation, SABS or WVE?

Do insiders and institutionals believe in SABS or WVE?

Do analysts rate SABS or WVE?

Is SABS or WVE more profitable?

Summary

How does SAB Biotherapeutics compare to Corvus Pharmaceuticals?

Which has more risk and volatility, CRVS or SABS?

Do insiders & institutionals have more ownership in CRVS or SABS?

Do analysts prefer CRVS or SABS?

Is CRVS or SABS more profitable?

Does the media prefer CRVS or SABS?

Which has preferable earnings & valuation, CRVS or SABS?

Summary

How does SAB Biotherapeutics compare to MeiraGTx?

Do analysts recommend MGTX or SABS?

Does the media favor MGTX or SABS?

Is MGTX or SABS more profitable?

Which has better valuation and earnings, MGTX or SABS?

Do insiders and institutionals hold more shares of MGTX or SABS?

Which has more volatility & risk, MGTX or SABS?

Summary

How does SAB Biotherapeutics compare to Oric Pharmaceuticals?

Which has stronger earnings and valuation, SABS or ORIC?

Does the media prefer SABS or ORIC?

Is SABS or ORIC more profitable?

Do analysts rate SABS or ORIC?

Do insiders and institutionals have more ownership in SABS or ORIC?

Which has more risk and volatility, SABS or ORIC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SABS vs. The Competition

SAB Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools